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Fibroblast activation protein (FAP) is a proline-selective protease that belongs to the S9
family of serine proteases. It is typically highly expressed in the tumor microenvironment
(TME) and especially in cancer-associated fibroblasts, the main cell components of the
tumor stroma. The exact role of its enzymatic activity in the TME remains largely unknown.
Hence, tools that enable selective, activity-based visualization of FAP within the TME can
help to unravel FAP’s function. We describe the synthesis, biochemical characterization,
and application of three different activity-based probes (biotin-, Cy3-, and Cy5-labeled)
based on the FAP-inhibitor UAMC1110, an in-house developedmolecule considered to be
the most potent and selective FAP inhibitor available. We demonstrate that the three
probes have subnanomolar FAP affinity and pronounced selectivity with respect to the
related S9 family members. Furthermore, we report that the fluorescent Cy3- and Cy5-
labeled probes are capable of selectively detecting FAP in a cellular context, making these
chemical probes highly suitable for further biological studies. Moreover, proof of concept is
provided for in situ FAP activity staining in patient-derived cryosections of urothelial tumors.
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INTRODUCTION
Fibroblast activation protein (FAP; EC3.4.21. B28), also called seprase, belongs to the S9 family of
serine proteases. Other members of this family include dipeptidyl peptidases 4, 8, and 9 (DPP4,
DPP8, and DPP9) and prolyl oligopeptidase (PREP) (Rawlings et al., 2018). FAP is a post-prolyl
proteolytic enzyme with endopeptidase as well as dipeptidyl peptidase activity, both exerted by the
same active site composed of Ser624-Asp702-His734 (O’Brien and O’Connor, 2008). FAP is expressed
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as a homodimeric transmembrane protein or as a soluble plasma
protease (antiplasmin cleaving enzyme, APCE) (Goldstein et al.,
1997; Piñeiro-Sánchez et al., 1997; Lee et al., 2006).
Typically, FAP is highly expressed in cancer-associated
fibroblasts (CAFs) in 90% of all epithelial tumors, whereas its
expression is low to undetectable in most healthy adult tissues
(Garin-Chesa et al., 1990). Besides its expression in the tumor
stroma, FAP expression is also upregulated in certain malignant
tumor cells, such as glioblastoma (Busek et al., 2016), breast
(Kelly et al., 1998), cervical (Jin et al., 2003), pancreatic (Shi et al.,
2012), and colorectal (Iwasa et al., 2003) cancer cells. Taken
together, it has been proven that FAP is a potential target for
cancer diagnostics and therapeutics. Moreover, FAP expression is
also increased in several nonmalignant diseases where active
tissue remodeling is involved, including hepatic fibrosis (Levy
et al., 1999), idiopathic pulmonary fibrosis (Acharya et al., 2006),
atherosclerosis (Brokopp et al., 2011), rheumatoid arthritis
(Bauer et al., 2006), and myocardial infarction (Tillmanns
et al., 2015).
Nevertheless, the main focus of FAP research lies within the
field of oncology. Elevated FAP expression and/or activity has
been detected in multiple human cancers and serves as a negative
prognostic marker for the overall survival time and progression of
the disease (Henry et al., 2007; Zhang et al., 2007; Cohen et al.,
2008; Ju et al., 2009). Furthermore, it has been proven that
FAP+CAFs contribute to tumor progression, resistance to
immunotherapy, and metastasis (Zi et al., 2015). FAP’s
endopeptidase activity (gelatinase activity) plays a major role
in remodeling of the extracellular matrix, which is an important
mechanism in the invasion and metastasis of the cancer cells
(Monsky et al., 1994; Lee et al., 2011). Additionally, its enzymatic
activity is also reported to have an angiogenesis promoting effect
(Huang et al., 2004). Lately, it was suggested that FAP also
contributes to immunosuppression in the tumor
microenvironment (TME). Firstly, Chen et al. found that
CAFs with high FAP expression are responsible for the
induction of immune checkpoint blockade resistance in a
colorectal cancer mouse model (Chen et al., 2017). Secondly,
Feig et al. demonstrated that the depletion of FAP+CAFs resulted
in immune control of pancreatic ductal adenocarcinoma tumors
(Feig et al., 2013). More recently, it was reported that FAP
promotes immunosuppression through upregulation of CCL2,
resulting in increased tumor growth by enhancing recruitment of
myeloid-derived suppressor cells and tumor-associated
macrophages (Yang et al., 2016; Lin et al., 2019).
In contrast to the above findings, other studies demonstrate
that elevated FAP expression is correlated with tumor
suppression instead of tumor promotion (Ariga et al., 2001;
Ramirez-Montagut et al., 2004). Hence, it is suggested that the
role of FAP in cancer is likely to depend on cell context and tumor
microenvironment.
Despite progress in understanding FAP biology, the enzyme’s
exact role in the TME remains largely unknown, in particular,
whether and how FAP’s proteolytic activity might be involved in
this context. Interestingly, most of the previous studies
investigating FAP’s function in cancer are relying on FAP
mRNA and/or protein expression rather than on the
investigation of FAP’s enzymatic activity. Quantification of the
latter could therefore offer alternative and/or complementary
information, especially because several studies have reported a
statistically relevant link between the enzymatic activity of FAP
and disease severity and progression (Cheng et al., 2005; Puré and
Blomberg, 2018). Therefore, activity-based probes (ABPs) for
FAP have the potential to unveil several functions of FAP in the
complex tumor environment. Moreover, these tools could also
offer value in FAP biomarker studies. Noteworthy, high FAP-
potency and selectivity towards the related enzymes are crucial
for these ABPs because the other S9 proteases are ubiquitously
expressed in human cells and tissues.
Earlier efforts from our groups delivered UAMC1110
(Figure 1A), the most potent and selective, orally bioavailable
FAP inhibitor reported to date (Ryabtsova et al., 2012; Jansen
et al., 2013; Jansen et al., 2014). Both we and others have used this
molecule as a main structural element of FAP-targeted ABPs
(Dvorakova et al., 2017; Simon et al., 2018; Bracke et al., 2019;
Zhang et al., 2020). Important examples include FAP probes for
PET/CT imaging and even radiotherapeutic applications
(Figure 1B–D) (Lindner et al., 2018; Loktev et al., 2019; Toms
et al., 2020; Kratochwil et al., 2019; Luo et al., 2020; Moon et al.,
2020). While these molecules might have unprecedented
potential for in vivo imaging of FAP-positive tumors, their
radioactivity impedes implementation for biomarker
applications outside the field of molecular imaging. In this
respect, ABPs with fluorometric or colorimetric read-out can
be expected to be highly relevant for these other domains of
biomarker research. Two types of compounds can be pursued: 1)
fluorogenic or colorigenic substrates of FAP and 2) FAP-
inhibitor-derived molecules equipped with a fluorophore, a
chromophore, or another label type that can be quantified via
standard molecular biology technology. Recently, our research
groups reported several UAMC1110-derived FAP substrates with
excellent cleavage efficiencies and selectivities (De Decker et al.,
2019) compared to other reported FAP-processed probes
(Figure 1E) (Bainbridge et al., 2017; Poplawski et al., 2013; Li
et al., 2012; Keane et al., 2013). Here, we present FAP-inhibiting
ABPs that contain a UAMC1110 moiety, equipped with either a
biotin, a Cy3, or a Cy5 moiety (Figure 1F). The choice to
introduce the label at the 6-position of the quinoline ring was
based on structure-activity relationship research that we
published earlier (Jansen et al., 2014). Likewise, several other
published UAMC1110-derived ABPs (shown, e.g., in Figure 1)
also indicated that large groups are accepted at this position
without taking significant affinity penalties (Figure 1).
Noteworthy, other fluorescent ABPs targeting FAP have been
reported very recently by Roy et al. (2020). It concerns conjugates
of a small molecule FAP inhibitor with either FITC or a near-
infrared fluorescent cyanine dye. The small molecule inhibitor
used as the basis for thesemolecules was claimed by the authors to
be FAP-selective, however, without providing experimental
details. The authors verified the selectivity of the derived
probes by using an in vitro fluorescence binding assay with
FAP-transfected HEK293T cells. This method, nonetheless,
does not constitute a reliable validation of selectivity with
respect to the other members of the S9 enzyme family.
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Furthermore, Konvalinka and coworkers published two types of
UAMC1110-derived ABPs both equipped with biotin or the
fluorophore ATTO488 (Dvorakova et al., 2017; Simon et al.,
2018). The first type consisted of polymer-bound, multivalent
probes called “iBodies”. These molecules showed high selectivity
towards recombinant DPP4, DPP9, and PREP based on IC50
experiments. Separately, structurally distinct compounds
obtained via a stochastic photomodification approach were
obtained. For the latter, only FAP-Ki values were reported, but
there were no selectivity data towards the other related family
members. Nonetheless, these compounds did not show aspecific
staining in FAP-negative cells, indicating in situ selectivity at least
under the experimental conditions used (Simon et al., 2018).
To support further investigation of FAP’s enzymatic function
in several pathological conditions, we decided to prepare three
different ABPs (biotin-, Cy3-, and Cy5-labeled) based on the
FAP-inhibitor UAMC1110. In order to provide a benchmark
status to these molecules for biomarker applications, unequivocal
characterization data are included with respect to target affinity,




The synthesis of the target compounds is summarized in Scheme
1. The alkyne-derived quinoline-4-carboxylate 1, obtained
relying on a procedure by Toms et al., was used as the starting
material (Poplawski et al., 2013). It was coupled with N-glycyl-
(4,4-difluoropyrrolidine-2-carbonitrile), delivering intermediate
4, the common precursor to the desired probe molecules. The
latter were obtained via copper-assisted azide-alkyne click
ligation of 4 and the corresponding, azide-derived biotin-,
FIGURE 1 | FAP-inhibitor UAMC1110 and examples of UAMC1110 derivatives that have been reported as activity-based probes (ABPs) (Jansen et al., 2014;
Lindner et al., 2018; De Decker et al., 2019; Loktev et al., 2019; Moon et al., 2020; Toms et al., 2020). (A) Parent compound UAMC1110 (Jansen et al., 2014). (B)
Gallium-68 labeled radiotracer reported in 2018 (Lindner et al., 2018). (C) Gallium-68 labeled radiotracer reported in 2020 (Moon et al., 2020). (D) Fluorine-18 labeled
radiotracer reported in 2019 (Toms et al., 2020). (E) Designed, selective FAP substrate reported in 2019 (De Decker et al., 2019). (F) UAMC1110-derived probes,
synthesized for this study.
SCHEME 1 | Overview of the synthetic preparation of target compounds 5–7.
Frontiers in Chemistry | www.frontiersin.org April 2021 | Volume 9 | Article 6405663
Van Rymenant et al. Fluorescent Fibroblast Activation Protein Activity-Based Probes
Cy3-, or Cy5-derived labels. The latter were acquired from
commercial sources. The biotin-, Cy3-, and Cy5-labeled probes
are referred to as compounds 5, 6, and 7, respectively. Detailed
procedures, yields, and compound characterization data are
provided in the Supporting Information file.
Enzymes
Recombinant human FAP (rhFAP, extracellular domain,
amino acid 27-760) with a C-terminal His-tag was expressed
and purified in Sf9 insect cells as described by Moon et al.
(Moon et al., 2020). Human dipeptidyl peptidase 4 (DPP4) was
purified from human seminal plasma as described before (De
Meester et al., 1996). Human recombinant dipeptidyl
peptidases 8 and 9 (DPP8 and DPP9) were expressed in Sf9
insect cells using the N-terminal BaculoDirect insect cell
expression system (Invitrogen) and were purified as
published before (De Decker et al., 2019). Human
recombinant prolyl oligopeptidase (PREP) was expressed in
BL21 (DE3) cells and purified as described by De Decker et al.
(2019).
Cell Culture, Transfection, and Stimulation
Human embryonic kidney cells (HEK293T) were purchased
from ATCC and were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS, 100 U/ml
penicillin, and 100 μg/ml streptomycin. Telomerase
immortalized colon cancer-associated fibroblasts (hTERT
CT5.3 CAFs) were cultured in DMEM supplemented with
10% FCS, 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin (De Vlieghere et al., 2015). Both cell
lines were maintained in a humidified incubator at 37°C with
5% CO2.
Transfection of HEK293T cells with FAP or an empty vector
(mock-transfection) was performed as described earlier (De
Decker et al., 2019). Briefly, HEK293T cells were transiently
transfected at 70–80% confluency with the pDEST40-hFAP
vector (encoding the full ORF of FAP) or pDEST40-empty
vector (Thermo Fisher) using the Lipofectamine 2000
transfection reagent (Thermo Fisher) in a 1:3 ratio of DNA/
Lipofectamine 2000. The HEK293T cells transfected with the
pDEST40-empty vector (mock-transfection) were used as a
negative control (De Decker et al., 2019). Cells were used 48 h
after transfection for the western blotting and/or (immuno)
fluorescence experiments.
Recombinant human TGF-β1 (PeproTech; 100–21-10UG)
was used for stimulation of CAFs. Briefly, 0.2 × 106 CAFs
were seeded in a T25 flask and incubated for 24 h.
Subsequently, the cells were stimulated with 10 ng/ml TGF-β1
for 4 days at 37°C in a 5% CO2 environment. Stimulated CAFs
were used for activity-based probe experiments.
Determination of IC50 for Fibroblast
Activation Protein, Dipeptidyl Peptidases 4,
8, and 9, and Prolyl Oligopeptidase
IC50 values of 5–7 (biotin-, Cy3-, and Cy5-labeled ABPs) for FAP
and PREP were determined as described by Moon et al. (Moon
et al., 2020). IC50 measurements for DPP4, DPP8, and DPP9 were
performed analogously using H-Gly-Pro-AMC as the substrate at
the respective final concentrations of 65 µM (with DPP4) and
100 µM (with DPP8/DPP9) at pH 7.6 (0.1 MTris-HCl buffer with
0.1 M NaCl and 0.1 mg/ml BSA). For all enzymes, the methods
and data fitting were performed as published by Moon et al.
(Moon et al., 2020). Experiments were repeated at least in
triplicate, and the results are represented as an average ± SD.
Reactivity of the Probes with Fibroblast
Activation Protein and Related Peptidases
Based on SDS-PAGE Analysis
To confirm the selectivity of Cy3-labeled 6 and Cy5-labeled 7,
100 nM enzyme was preincubated for 15min at 37°C.
Subsequently, the enzymes were incubated for 20min at 37°C
with various concentrations of either Cy3 or Cy5 ABP (2.5, 0.5,
0.1, 0.02, and 0 µM) in, respectively, FAP assay buffer (50mM Tris-
HCl pH 8.0, 140mM NaCl), DPP assay buffer (0.1M Tris-HCl
buffer with 0.1M NaCl pH 7.6), or PREP assay buffer (0.1MK-
phosphate, 1 mM EDTA, 1 mM DTT pH 7.4). After 20 min
incubation, the samples were boiled in 4x reducing SDS-PAGE
loading buffer for 5 min and loaded on a 7.5% separation gel. The
gels were run for 1 h at 140 V with the PageRuler™ Plus Prestained
Protein marker (Life Technologies). Afterward, the Cy5-labeled gels
were directly scanned at the red 700 nm (red channel for Cy5)
channel of the Odyssey Sa fluorescence imaging system (Li-COR),
and the images were analyzed using the Image Studio software
(version 5.2). For the Cy3 experiments, the gels were scanned at the
green channel (520 nm, Cy3 probe) and red channel (630 nm,
molecular weight marker) using the Amersham 600 RGB imager,
and image acquisition was performed with the ImageJ software.
Reversibility of the Probes Based on a
Dialysis Experiment
Recombinant human FAP (rhFAP) was incubated for 15 min at
37°C with a concentration of probe that was predicted to inhibit
around 90% of FAP’s activity (5: 1.08 nM; 6: 2.50 nM; 7: 1.35 nM;
UAMC1110: 0.77 nM diluted in FAP assay buffer: 50 mM Tris-HCl
pH 8.0, 140mM NaCl, and 1mg/ml BSA). As a solvent control,
rhFAP was incubated with 0.0002% DMSO. After 15 min of
incubation, FAP activity was determined as published by Bracke
et al. (2019). Subsequently, the samples were dialyzed at 4°C against
FAP assay buffer (using a 10 kDa cut-off Slide-A-Lyzer MINI
dialysis device (Thermo Fisher). Buffer (14ml) was exchanged
after 3 h, 6 h, 24 h, 3 days, and 7 days, and after each of these
time points, a FAP activity measurement was performed. For the
UAMC1110 parent compound, FAP activity was only measured on
days 3 and 7.
Fibroblast Activation Protein Labeling in
Cell Lysates Using the Cy5 Probe by
SDS-PAGE and Western Blotting
HEK293T cells were transfected with pDEST40-hFAP or
pDEST40-empty vector in T25 flasks following the protocol
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described in Cell Culture, Transfection, and Stimulation. After
48 h, cells were washed 3 times with DPBS followed by harvesting
using a cell scraper. Cells were centrifuged at 250 x g for 5 min at
4°C. TGF-β1-stimulated CAFs were harvested using a
nonenzymatic dissociation solution (Sigma-Aldrich) and
centrifuged at 125 x g for 5 min at 4°C.
The harvested cells were lysed in western blot lysis buffer (1%
Triton X-100, 150 mM NaCl, 5 mM EDTA, and a complete
protease inhibitor cocktail tablet [Roche Diagnostics] in a
50 mM Tris buffer, pH 7.5) for 1 h with frequent agitation
and centrifuged at 12,000 × g for 10 min at 4°C. The supernatant
was used for western blot analysis. Protein concentration was
determined using the Bradford protein quantification assay.
20 µg of HEK293T lysates and 50 µg of CAF lysate were
incubated with 200 nM of Cy5-labeled 7 for 20 min at 37°C.
Subsequently, the samples were diluted in 4x SDS-PAGE sample
buffer, boiled, and subjected to SDS-PAGE (7.5% acrylamide
gels, 140 V, 1 h) followed by protein transfer onto a low
fluorescence PVDF membrane (Bio-Rad, 250 mA, 1 h).
Membranes were cut into two above 50 kDa. Subsequently,
the membranes were blocked with 2.5% BSA in TBS-T for
1 h at room temperature followed by overnight incubation at
4°C with a primary antibody against FAP (Rabbit anti-FAP,
Abcam, Ab207178, 1:1,000 diluted in 1% BSA in TBS-T).
β-Actin was used as a loading control (mouse anti-β-actin,
Sigma, A1978, 1:10,000 diluted in 1% BSA in TBS-T).
Afterward, the membranes were incubated with fluorescent
secondary antibodies (IRDye® 800CW, goat anti-rabbit, and
IRDye® 800 CW donkey anti-mouse, LI-COR, 1:10,000 in 1%
BSA in TBS-T) for 1 h at room temperature. Between the
different incubations, the membranes were washed 5 × 5 min
with TBS-T. Membranes were afterward simultaneously
scanned at an excitation of 685 nm (Cy5-labeled probe 7;
700 nm channel) and 785 nm (secondary antibody; 800 nm
channel) using the odyssey Sa fluorescence imaging system
(LI-COR). Images were analyzed using the Image Studio
software (version 5.2).
In Situ Detection of Fibroblast Activation
Protein Expression and/or Activity in
Fibroblast Activation Protein-Transfected
HEK293T by (Immuno)fluorescence
The day before transfection, 80,000 cells HEK293T were seeded
into 8-well Nunc Lab-Tek II CC2 Chamber Slides (Life
Technologies). After 24 h, the cells were transfected with
pDEST40-hFAP or pDESR40-empty vector using the protocol
described in Cell Culture, Transfection, and Stimulation. After
transfection, the HEK293T cells were washed twice with DPBS
followed by incubation with 500 nM of either Cy3-labeled 6 or
Cy5-labeled 7 (diluted in Opti-MEM) for 2 h at 37°C in the dark.
Next, cells were washed twice with DPBS followed by fixation
with 4% paraformaldehyde (PFA) for 30 min at room
temperature. The PFA was gently removed, and the fixed cells
were then washed twice with DPBS followed by a blocking step in
5% BSA for 1 h at room temperature. Subsequently, the cells were
incubated with the anti-FAP F19 monoclonal antibody (purified
in-house; 1.43 mg/ml; 1:500 in 3% BSA in DPBS) overnight at 4°C
in the absence of light. The antibody was removed, and the cells
were washed twice with DPBS followed by incubation with a
secondary antibody (Alexa Fluor 488 Goat anti-Mouse, A11001,
Life Technologies) for 1 h at room temperature in the absence of
light and a similar washing procedure. The slides were mounted
using Vectashield antifade mounting medium with DAPI (Vector
lab, H-1200).
For the confocal microscopy analysis, an inverted Leica TCS
SP8 confocal laser scanning microscope was used. DAPI was
detected by the DAPI channel (405 nm), and the Cy3 probe and
Cy5 probe were detected with a white light laser (WLL) at the
respective wavelengths of 554 and 645 nm. The secondary
antibody (Alexa Fluor 488) was visualized with a WLL at
495 nm. Images were made with 63x objective and 1.5x zoom
and analyzed using the ImageJ software. All images were taken
under the same settings.
Proof of Concept for Detection of In Situ
Fibroblast Activation Protein Activity in
Fibroblast Activation Protein-Positive
Urothelial Cancer Cryosections
Fresh frozen urothelial cancer tissue was purchased from BioIVT
(patient ID: ILS51040FT2). The tissue was optimal cutting
temperature (OCT) compound embedded, and cryosections of
5 µm were made using a Leica CM1950 cryostat. Samples were
stored at –80°C until use.
The urothelial cryosections were thawed at room temperature,
and thereafter the tissue was lined with an IHC PAP pen (Enzo Life
Sciences). The lined tissue sections were then washed 2 times for
5 min with DPBS, followed by two washes (5 min) with 50mM
Tris-HCl pH 7.4, 140 mM NaCl. Subsequently, the sections were
incubated with either probe 6 or 7 (1 µM in FAP assay buffer,
200 µL) for 2 h at 37°C in a humidified chamber in the dark. After
washing (3 × 5 min with DPBS), the sections were fixed with 4%
paraformaldehyde (PFA) for 10min at room temperature. Next,
sections were washed three times and the slides were mounted as
described above.
Imageswere obtained using aZeissAxio imager.DAPIwas detected
using the DAPI channel, and the Cy3 and Cy5 probe were detected
with a Colibri 7 LED light source at the respective excitation
wavelengths of 548 and 650 nm. Images were made using a 20×
objective, and image analysis was performed using the ImageJ software.
RESULTS AND DISCUSSION
Fibroblast Activation Protein Affinity and
Selectivity of Probes 5–7
All three ABPs were characterized for their potency toward FAP
and selectivity toward the related peptidases (DPP4, DPP8, DPP9,
and PREP). The results are displayed in Figure 2A. Parent
compound UAMC1110 was used as a reference compound.
Compared to Jansen et al., a slightly higher potency for
UAMC1110 toward FAP is reported here (0.43 vs. 3.2 nM).
The latter is due to the introduction of a new measurement
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method using a lower concentration of human recombinant FAP
(Jansen et al., 2014).
All three ABPs exhibited subnanomolar affinity toward
human recombinant FAP, within the same order of magnitude
as the parent compound (Figure 2A). These results provide
additional evidence that derivatization of UAMC1110 at the 6-
position of the quinoline ring tolerates the introduction of diverse
and sterically large groups.
IC50 values for DPP4, DPP8, DPP9, and PREP are in the low
micromolar range, corresponding to ∼1000-fold selectivity for 5
and 6. Nevertheless, under the experimental conditions used here,
compound 7 (the Cy5 probe) exhibits some cross-reactivity with
DPP8 and DPP9 (Figure 2A).
To confirm the selectivity of probes 5–7, an in vitro labeling
experiment using recombinant FAP, DPP4, DPP8, DPP9, and
PREP was performed. The latter consisted of preincubating
different probe concentrations with 100 nM of the respective
enzymes, after which the mixtures were submitted to SDS-PAGE
electrophoresis and, ultimately, detection of labeled enzymes. For
biotin-labeled 5, a streptavidin-HRP-based method was used for
visualization of labeled enzymes (Supplementary Method 2.1).
This however did not result in significant staining (data not
shown). Although we do not have a clear explanation for this, we
assume that steric hindrance could be involved here. More
specifically, it is possible that when 5 is bound to FAP, the
biotin label is buried in FAP’s structure, resulting in steric
hindrance that prevents binding to streptavidin. Conversely,
proteins labeled with fluorescent 6 and 7 were easily detected
at the fluorophores’ respective wavelengths of maximum
fluorescence (λmax) (Figures 2B,C). Nonetheless, it should be
mentioned that, due to the differences in λmax values for both
fluorophores, it was required to use two different instruments for
detecting 6 and 7 during the SDS-PAGE experiment. Therefore, a
direct comparison of sensitivity under experimental conditions is
difficult. In general, the observed fluorescent labeling experiments
reflect the selectivity of the probes determined in the IC50
FIGURE 2 | Potency, selectivity, and irreversibility of the ABPs (5, 6, and 7) for FAP. (A) IC50 values of 5–7 (biotin-, Cy3-, and Cy5-activity-based probe) toward FAP
and related peptidases (DPP4, DPP8, DPP9, and PREP). Experiments were carried out in triplicate (n  3), and results are displayed as mean ± SD. Labeling of
recombinant FAP, DPP4, DPP8, DPP9, and PREP using 6 (Cy3-labeled) (B) and 7 (Cy5-labeled) (C) probes. Enzymes (100 nM final concentration) were incubated
separately with various probe concentrations for 20 min and then subjected to SDS-PAGE analysis. (D) Dialysis experiment to investigate reversibility of the
developed probes (n  2). N.D.: not determined.
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experiments. Fluorescent FAP labeling with 7 (Cy5-labeled probe)
is visible down to 20 nM probe concentration, whereas with 6
(Cy3-labeled probe), FAP can be visualized down to 100 nM probe
concentration. Since FAP’s concentration in the experiment is
100 nM, this corresponds, respectively, to a 1:1 (Cy3) and 0.2:1
(Cy5) probe/enzyme concentration ratio. Furthermore, almost no
cross-reactivity is observed with DPP4 and PREP, while some
cross-reactivity with DPP8 and DPP9 can be observed for both
the Cy3- and Cy5-based molecule, again approximately
proportional to the IC50 values of these compounds (Figures
2B,C). Overall, it is surprising that cross-reactivity toward
DPP8/9 is observed in SDS-PAGE. This finding suggests a
“tight binding” profile, despite the relatively lower inhibitory
potencies of 6 and 7 toward DPP8/9. Nonetheless, it is also
worth mentioning that an overall lower potency does not per se
preclude the formation of a covalent bond between the active
site serine residue and the carbonitrile warhead of 6 and 7.
Structural studies (e.g., X-ray diffraction of [inhibitor-protease]
complexes) could shed more light on this issue. Full gel scans of
6 (Cy3) and 7 (Cy5) in gel scanning experiments are displayed
in Supplementary Figure S1, S2.
That we were able to detect the complex of FAP with the
fluorescent Cy3 and Cy5 probes after performing SDS-PAGE
shows that the compounds bind very tightly to FAP’s active site.
To rationalize this observation, a covalent interaction of the
carbonitrile warhead in these compounds and FAP’s catalytic
serine residue can reasonably be assumed. This leads to the
formation of an imidate adduct, as suggested by earlier
Structure-Activity-Relationship (SAR) studies that we have
performed on the class of inhibitors to which parent
compound UAMC1110 belongs (Jansen et al., 2014).
Comparably, crystallographic evidence for imidate formation
has been delivered for structurally related inhibitors of DPP4
(Berger et al., 2018). Nonetheless, this covalent interaction is
known to be transient and reversible, and we have earlier also
established the reversible, covalent binding profile of the probes’
parent compound UAMC1110 (Jansen et al., 2014). To further
investigate the probes’ binding profile, a dialysis experiment was
performed (Figure 2D). The results of the latter indeed confirm
that when FAP was incubated with the probes followed by
extensive dialysis, the recovery of FAP activity is more limited
compared to the parent compound UAMC1110. We conclude
therefore that 6 and 7 practically behave as irreversible inhibitors
of FAP within the conditions and the timeframes of our
experiments. These observations were in line with the
previously published FAP-targeting iBody report. Here, no
FIGURE 3 | FAP labeling in FAP-transfected HEK293T (A) and TGF-β1-stimulated CAF cells (B) using compound 7 (Cy5-labeled probe). Cell lysates were
incubated with 200 nM of 7 (Cy5 probe) for 30 min at 37°C, followed by SDS-PAGE and western blot analysis. The red bands (700 nm channel) correspond to FAP
labeling with the Cy5 probe, whereas the green bands (800 nm channel) correspond to FAP labeling with a selective anti-FAP antibody. β-Actin was used as loading
control for FAP- and mock-transfected HEK293T cells. In-house purified rhFAP was loaded as positive control. The Cy5 probe is selective towards FAP in both the
HEK293T (A) and CAF cell lines (B), as confirmed by co-labeling of the Cy5 probe (red) with the anti-FAP antibody (green).
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koff-rates using surface plasmon resonance (SPR) could be
measured (Dvorakova et al., 2017).
Furthermore, using classical dilution-based enzyme kinetics
experiments, no activity recovery could be detected, also
indicating very low koff-rates. In summary, these probes possess
a remarkable “tight binding” profile, in which the [ligand-target]
complex is significantly more stable than any other carbonitrile-
based inhibitor that we have investigated to date. It cannot be
excluded that other moieties of the probes than the carbonitrile
warhead alone are involved in this process. Although cyanine-
based dyes have not been reported to covalently label proteins, it
cannot be excluded that in these compounds they contribute to
binding via other physicochemical interactions with FAP (e.g.,
ionic interactions with the sulfonate groups).
Selective Labeling of Fibroblast Activation
Protein with Probe 7 (Cy5-Labeled) in Cell
Lysates
Based on the IC50 and the in-gel fluorescence SDS-PAGE
experiments, we concluded that Cy5-labeled 7 was the most
potent probe toward FAP. Because 7 showed most cross-
reactivity with other S9 enzyme family members, we investigated
whether this probe can be used to selectively label active FAP in cell
FIGURE 4 | FAP activity labeling with probes 6 (Cy3-labeled) and 7 (Cy5-labeled) in FAP-transfected HEK293T cells. (A) Clear membrane colocalization of the Cy3
probe (red) and the F19 anti-FAP antibody (green), indicating selectivity of the fluorescent Cy3 probe. (B) The Cy5 probe caused cytoplasmatic staining, whereas the
antibody is mainly visible at the membrane, suggesting an internalization of the FAP-Cy5 complex. No aspecific stainings were visible in the mock-transfected
HEK293T cells. Images are representative of at least two independent experiments (n  2).
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lysates. To this end, we prepared lysates from FAP- and mock-
transfected HEK293T cells and TGF-β1-stimulated CAFs. Cell
lysates were incubated with 200 nM of the Cy5 probe, and the
mixtures were subjected to SDS-PAGE, followed by western blot
analysis. The results demonstrated that 7 (red) can selectively label
overexpressing and endogenous FAP in the cell lysates, as confirmed
by colabeling with the anti-FAP antibody (green) (Figures 3A,B).
No labeling of FAP in the mock-transfected cells is observed, again
confirming selective labeling. To demonstrate the endogenous
DPP8/9 expression/activity pattern in FAP- and mock-
transfected HEK293T cells and CAFs, a western blotting
experiment and DPP8/9 activity measurement were performed
(Supplementary Figure S3). This experiment indicated that 7
displayed a high selectivity toward FAP, under the reaction
conditions used in this experiment. Remarkably, in both the
FAP-transfected HEK293T lysates and the CAF lysates, the Cy5
probe seems to label FAP at equal sensitivity compared to the anti-
FAP antibody, implying that this probe can be used as an alternative
for antibodies in the detection of active FAP in a biological context.
Given that Cy5-labeled 7 could selectively label FAP in these
lysates, we assume that also the Cy3 probe is capable of doing so,
especially because of its comparable FAP affinity and higher
selectivity toward DPP8 and DPP9. Nevertheless, performing
similar experiments in the future may be necessary to prove this
hypothesis.
In Situ Detection of Active Fibroblast
Activation Protein by Fluorescence
Microscopy in Fibroblast Activation
Protein-Transfected HEK293T Cells
Next, we used both 6 and 7 to detect FAP activity in HEK293T-
transfected cells by fluorescence microscopy.
With the Cy3-labeled 6, a clear membrane-bound FAP
staining was visible on the FAP-transfected HEK cells
(Figure 4A). The selectivity of 6 was confirmed by colabeling
of FAP with this ABP (red) and the monoclonal F19 anti-FAP
antibody (green). Mock-transfected HEK293T cells were used as
FIGURE 5 | Staining of active FAP in the tumor microenvironment of urothelial cancer sections using 6 (Cy3-probe) and 7 (Cy5-probe). Images are representative of
at least three different tissue sections for each activity-based probe (n  3).
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a negative control and again proved that no aspecific staining was
present for both the Cy3 probe and the antibody.
In contrast to 6, the Cy5-labeled 7 caused a cytoplasmatic staining
rather than a membrane staining (Figure 4B). However, there is only
Cy5 cytoplasmatic staining visible in the HEK293T cells that were
successfully transfected with pDEST40-hFAP. In addition, no Cy5
staining was visible at the mock-transfected HEK293T cells. Given
that HEK293T cells endogenously express DPP8 and DPP9 and no
staining is visible in themock-transfected cells, we conclude that the Cy5
probe specifically binds to FAP. To rationalize this observation, an
internalizationof FAPuponbindingwith theCy5probe canbe assumed.
This is in line with a previously published study that demonstrated FAP
internalization upon binding with an ATTO488 conjugated FAP-iBody,
also based on the parent UAMC1110 compound (Dvorakova et al.,
2017). Furthermore, it is also known that the F19 monoclonal anti-FAP
antibody does not initiate FAP internalization, not even at 37°C (Fischer
et al., 2012). Nonetheless, for a more precise explanation for Cy5-FAP
complex internalization in contrast to Cy3-FAP membrane staining,
more mechanistic studies are needed.
With biotin-labeled 5, a similar in situ staining experiment in
FAP-transfected HEK293T cells was performed following the
method described in the Supplementary Material. Unfortunately,
we were not able to visualize FAP on the cells using the biotin-
labeled probe (data not shown). This is in line with the observations
during the western blotting experiments and again could indicate
possible steric hindrance for binding with streptavidin. Hence, no
further experiments with biotin-labeled 5 were performed.
Proof of Concept for Detection of Active
Fibroblast Activation Protein in Human
Urothelial Bladder Cancer Using Probes 6
and 7
To investigate 6 and 7’s ability to label active FAP in the tumor
stroma, both were used to stain human urothelial cancer
cryosections. A clear staining of FAP activity is visible for both 6
and 7 under the conditions used in this experiment (Figure 5). Based
on morphology, the FAP staining is clearly restricted to the tumor
stroma, whereas almost no staining was visible in the tumor cells
themselves, indicating selective labeling since FAP is only known to
be expressed in the tumor stroma of urothelial cancer (whole slide
image, Supplementary Figure S4) (Mezheyeuski et al., 2020).
CONCLUSION
In this work, we developed three FAP-specific activity-based
probes (biotin-, Cy3-, and Cy5-labeled) with a subnanomolar
affinity toward FAP and pronounced selectivity toward the
related S9 family members. Moreover, it was concluded that the
ABPs bind very tightly to the active site of FAP, resulting in the
practically irreversible character of the compounds. We further
demonstrated that Cy5-labeled 7 could selectively label not only
overexpressed but also endogenous FAP in cell lysates. Finally, we
showed the applicability of both the Cy3-labeled 6 and Cy5-labeled
7 for in situ FAP labeling in cells and cancer cryosections.
Unfortunately, we were not able to visualize FAP labeled with
biotin-based probe 5, in neither theWestern blotting experiments
nor the in situ staining of FAP-transfected HEK293T cells. In the
future, investigating FAP-specific biotin probes with a longer
linker may lead to more promising results.
Consequently, the newly developed ABPs can be considered as
useful chemical tools that have several advantages compared to the
classical immunochemical techniques (e.g., immunofluorescence). First
of all, staining of FAP in cells and/or tissues is much faster using
fluorescent ABPs compared to general antibody-relying techniques,
resulting in significant time savings. Secondly, ABPs are much smaller
than antibodies, making it possible to use ABPs for in situ protein
interaction and colocalization studies. Where larger antibodies can
cause steric hindrance in such studies, small-molecule ABPs could be
very suitable for accurate protein-interaction experiments.
In summary, we have developed FAP-selective fluorescent
ABPs, which allow accurate detection of active FAP in cells
and tissue cryosections. The developed FAP-selective ABPs
can be used to facilitate the understanding of FAP’s enzymatic
activity in the tumor microenvironment. Finally, given the
importance of FAP not only in the pathophysiology of cancer
but also in several other diseases (idiopathic pulmonary fibrosis,
rheumatoid arthritis, atherosclerosis, hepatic fibrosis, etc.), the
applicability of these newly developed probes could be extended
to unravel FAP’s role in these diseases as well.
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